Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients

Ibezapolstat outperformed vancomycin showing eradication of fecal C. difficile at Day 3 of treatment in 15 of 16 treated patients (94%), versus vancomycin...

Related Keywords

United States ,University Of Houston ,Texas ,Houston ,America ,Davidp Luci ,Kevin Garey ,Robertj Deluccia ,Acurx Pharmaceuticals ,Society Or Healthcare Epidemiology Of America ,Company Ph ,Company Scientific Advisory Board ,Exchange Commission ,Data Monitoring Committee ,University Of Houston College Pharmacy ,Trial Oversight Committee ,European Medicines Agency ,Drug Administration ,Nasdaq ,Exchange Commission On Form ,Acurx Pharmaceuticals Inc ,Infectious Diseases Society Of America ,Extended Clinical Cure ,Gulf Coast Consortia Antimicrobial Resistance ,Houston College ,Principal Investigator ,Acurx Scientific Advisory Board ,Double Blind Study ,Ibezapolstat Compared ,Executive Chairman ,Ibezapolstat Phase ,Scientific Advisory Board ,Clinical Cure ,Modified Intent ,Treat Population ,Per Protocol Population ,Prescribing Information ,Independent Data Monitoring Committee ,Fast Track Designated ,Gram Positive Selective Spectrum ,Qualified Infectious Disease Product ,Generating New Antibiotic Incentives Now ,Clinical Practice Guidelines ,Infectious Diseases Society ,Healthcare Epidemiology ,New England Journal ,Bile Acid ,Private Securities Litigation Reform Act ,Nc ,